KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Humana (HUM) Other Non Operating Income (2018 - 2025)

Humana (HUM) has disclosed Other Non Operating Income for 7 consecutive years, with -$53.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income changed N/A to -$53.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$264.0 million, a N/A change, with the full-year FY2025 number at -$451.0 million, down 149.17% from a year prior.
  • Other Non Operating Income was -$53.0 million for Q4 2025 at Humana, up from -$163.0 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $1.1 billion in Q3 2021 to a low of -$419.0 million in Q2 2021.
  • A 4-year average of $16.0 million and a median of -$30.0 million in 2021 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: surged 15557.14% in 2021, then tumbled 775.0% in 2023.
  • Humana's Other Non Operating Income stood at -$30.0 million in 2021, then crashed by 180.0% to -$84.0 million in 2022, then skyrocketed by 107.14% to $6.0 million in 2023, then crashed by 983.33% to -$53.0 million in 2025.
  • Per Business Quant, the three most recent readings for HUM's Other Non Operating Income are -$53.0 million (Q4 2025), -$163.0 million (Q1 2025), and $6.0 million (Q3 2023).